13-Week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel trial of 2 different dose regimens of lumiracoxib (100 mg od [once daily] and 200 mg od initial dose for two weeks followed by 100 mg od) in patients with primary knee osteoarthritis, using celecoxib (200 mg od) as a comparator

Trial Profile

13-Week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel trial of 2 different dose regimens of lumiracoxib (100 mg od [once daily] and 200 mg od initial dose for two weeks followed by 100 mg od) in patients with primary knee osteoarthritis, using celecoxib (200 mg od) as a comparator

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2006

At a glance

  • Drugs Celecoxib; Lumiracoxib
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top